"Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults-A systematic review".
QR678
androgenetic alopecia
biomimetic polypeptides
growth factors
hair regrowth treatments
minimally invasive therapies
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
received:
29
05
2024
accepted:
05
07
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
Androgenetic alopecia is the most common cause of hair loss that affects over 50% of the world population. It is a condition that is multifactorial in origin, with no specific causative factor, making treatment an enervating experience for the patient as well as the doctor. In recent times, a number of modalities have been introduced for the treatment of alopecia. However, the evidence supporting them is unstructured and sparse. Therefore, this article aims to explore the current trends in minimally invasive treatments for the management of androgenetic alopecia. An in-depth literature search on injectables used in the treatment of alopecia in PubMed/MEDLINE, Embase, PsycINFO, TRIP Cochrane Library, and Cochrane Skin databases between January 2000 and May 2023 was performed. The studies included were randomized controlled trials, non-randomized trials, quasi trials, single arm interventions, and cohort studies. Sixteen of the 1071 studies that were found during the original search were accepted in accordance with the inclusion criteria. Twelve studies assessed the effectiveness of the injectable group by comparing it to a control group consisting of saline, distilled water, and topical minoxidil. In the treatment of alopecia, dutasteride and injectable growth factor formulations achieved clinically significant results. The usage of injectables and topical medicines to treat hair loss has increased in the recent years. Overall results from clinical investigations, pilot studies, and trials looking at the efficacy and safety of these growth factors in the AGA show satisfactory efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Androgenetic alopecia is the most common cause of hair loss that affects over 50% of the world population. It is a condition that is multifactorial in origin, with no specific causative factor, making treatment an enervating experience for the patient as well as the doctor. In recent times, a number of modalities have been introduced for the treatment of alopecia. However, the evidence supporting them is unstructured and sparse. Therefore, this article aims to explore the current trends in minimally invasive treatments for the management of androgenetic alopecia.
METHODS
METHODS
An in-depth literature search on injectables used in the treatment of alopecia in PubMed/MEDLINE, Embase, PsycINFO, TRIP Cochrane Library, and Cochrane Skin databases between January 2000 and May 2023 was performed. The studies included were randomized controlled trials, non-randomized trials, quasi trials, single arm interventions, and cohort studies.
RESULTS
RESULTS
Sixteen of the 1071 studies that were found during the original search were accepted in accordance with the inclusion criteria. Twelve studies assessed the effectiveness of the injectable group by comparing it to a control group consisting of saline, distilled water, and topical minoxidil. In the treatment of alopecia, dutasteride and injectable growth factor formulations achieved clinically significant results.
CONCLUSION
CONCLUSIONS
The usage of injectables and topical medicines to treat hair loss has increased in the recent years. Overall results from clinical investigations, pilot studies, and trials looking at the efficacy and safety of these growth factors in the AGA show satisfactory efficacy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759‐3781. doi:10.1111/jocd.14537
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. ndian J Dermatol Venereol Leprol. 2013;79:613. doi:10.4103/0378-6323.116730
Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. MDText.com, Inc; 2000. Accessed February 27, 2023. http://www.ncbi.nlm.nih.gov/books/NBK278957/
Kapoor R, Shome D, Doshi K, Patel G, Vadera S. Evaluation of efficacy of QR678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS—a prospective study. J Cosmet Dermatol. 2020;19(10):2637‐2646. doi:10.1111/jocd.13673
Kapoor R, Shome D, Vadera S, Kumar V, Ram MS. QR678 & QR678 neo hair growth formulations: a cellular toxicity & animal efficacy study. Plast Reconstr Surg Glob Open. 2020;8(8):e2843. doi:10.1097/GOX.0000000000002843
Kumar V, Shome D, Atre SY, et al. The iceberg phenomenon of alopecia associated public health ramifications on the quality of life among adults in India. Dermatol Rev. 2022;4:180‐188. doi:10.1002/der2.109
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth—safety and efficacy evaluation in a first‐in‐man pilot clinical study. J Cosmet Laser Ther. 2018;20(6):369‐379. doi:10.1080/14764172.2018.1439965
Lueangarun S, Visutjindaporn P, Parcharoen Y, Jamparuang P, Tempark T. A systematic review and meta‐analysis of randomized controlled trials of United States Food and Drug Administration‐approved, home‐use, low‐level light/laser therapy devices for pattern hair loss: device design and technology. J Clin Aesthet Dermatol. 2021;14(11):E64‐E75.
Kanti V, Messenger A, Dobos G, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men—short version. J Eur Acad Dermatol Venereol. 2018;32(1):11‐22. doi:10.1111/jdv.14624
Roberts JL, Fiedler V, Imperato‐McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5α‐reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555‐563. doi:10.1016/S0190-9622(99)80052-8
el Samahy MH, Fahmy HM, El Sawaf SI, Mostafa AE. Lyophilized growth factor intralesional injection in female pattern hair loss: a clinical and trichoscopic study. Dermatol Ther. 2021;34(2):e14867. doi:10.1111/dth.14867
Zimber M, Ziering C, Zeigler F, et al. Hair regrowth following a Wnt‐ and follistatin containing treatment: safety and efficacy in a first‐in‐man phase 1 clinical trial. J Drugs Dermatol. 2011;10:1308‐1312.
Bruce AJ, Pincelli TP, Heckman MG, et al. A randomized, controlled pilot trial comparing platelet‐rich plasma to topical minoxidil foam for treatment of androgenic alopecia in women. Dermatologic Surg. 2020;46(6):826‐832. doi:10.1097/DSS.0000000000002168
Sharma A, Surve R, Dhurat R, et al. Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. J Biol Regul Homeost Agents. 2020;34(2):659‐661. doi:10.23812/19-385-L-51
Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2016;348:175‐188. doi:10.1055/s-0041-111066
Moher D, Chan A‐W. SPIRIT (standard protocol items: recommendations for interventional trials). In: Moher D, Altman DG, Schulz KF, Simera I, Wager E, eds. Guidelines for Reporting Health Research: A User's Manual. John Wiley & Sons; 2014:56‐67. 10.1002/9781118715598.ch7
Schulz K, Altman D, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726‐732. doi:10.7326/0003-4819-152-11-201006010-00232
The Cochrane collaboration. Review Manager (RevMan). 2020.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712‐716. doi:10.1046/j.1445-2197.2003.02748.x
Abdallah M, El‐Zawahry K, Besar H. Mesotherapy using dutasteride‐containing solution in male pattern hair loss: a controlled pilot study. 2009;20:1.
Kapoor R, Shome D, Vadera S, Ram MS. QR678 & QR678 neo vs PRP—A randomised, comparative, prospective study. J Cosmet Dermatol. 2020;19(11):2877‐2885. doi:10.1111/jocd.13398
Shome D, Kapoor R, Vadera S, Doshi K, Patel G, Mohammad KT. Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 neo® hair regrowth formulation for the treatment of androgenetic alopecia—a prospective study. J Cosmet Dermatol. 2021;20(10):3299‐3307. doi:10.1111/jocd.14139
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246e‐248e. doi:10.1097/PRS.0b013e3181ef816d
Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163‐167. doi:10.4103/JCAS.JCAS_77_17
Shon U, Kim MH, Lee DY, Kim SH, Park BC. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020;83(6):1838‐1839. doi:10.1016/j.jaad.2020.04.082
Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and safety of botulinum toxin type a in the treatment of androgenetic alopecia. Biomed Res Int. 2020;2020:1‐7. doi:10.1155/2020/1501893
Uzel BPC, Takano GHS, Chartuni JCN, et al. Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo‐controlled trial. Dermatol Ther. 2021;34(1):e14622. doi:10.1111/dth.14622
Doghaim NN, El‐Tatawy RA, Neinaa YME, Abd El‐samd MM. Study of the efficacy of carboxytherapy in alopecia. J Cosmet Dermatol. 2018;17(6):1275‐1285. doi:10.1111/jocd.12501
Gajjar P, Mehta H, Barvaliya M, Sonagra B. Comparative study between mesotherapy and topical 5% minoxidil by dermoscopic evaluation for androgenic alopecia in male: a randomized controlled trial. Int J Trichology. 2019;11(2):58‐67. doi:10.4103/ijt.ijt_89_18
Kwaan MR, Melton GB. Evidence‐based medicine in surgical education. Clin Colon Rectal Surg. 2012;25(3):151‐155. doi:10.1055/s-0032-1322552
Mwita C. Systematic reviews in surgical decision making: unpacking the data. Ann Afr Surg. 2018;14:14. doi:10.4314/aas.v14i1.8
Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457‐463.
Moftah N, Moftah N, Abd‐Elaziz G, et al. Mesotherapy using dutasteride‐containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686‐693. doi:10.1111/j.1468-3083.2012.04535.x
Inui S, Itami S. Molecular basis of androgenetic alopecia: from androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011;61(1):1‐6. doi:10.1016/j.jdermsci.2010.10.015
Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type a on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesth Plast Surg. 2010;34(4):424‐427. doi:10.1007/s00266-009-9423-z
de Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985;121(2):197‐202. doi:10.1001/archderm.121.2.197
Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo‐controlled, double‐blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767‐774. doi:10.1016/j.jaad.2007.04.012
Shome D, Kapoor R, Doshi K, Patel G, Vadera S, Kumar V. Comparison of QR678® & QR678® neo as monotherapy and as combination therapy with 5% minoxidil solution and oral finasteride in the treatment of male androgenetic alopecia—which is better? J Cosmet Dermatol. 2021;20(6):1763‐1765. doi:10.1111/jocd.14154
Metwally D, Abdel‐Fattah R, Hilal RF. Comparative study for treatment of alopecia areata using carboxy therapy, intralesional corticosteroids, and a combination of both. Arch Dermatol Res. 2022;314(2):167‐182. doi:10.1007/s00403-021-02201-6
Philpott MP, Sanders DA, Kealey T. Effects of insulin and insulin‐like growth factors on cultured human hair follicles: IGF‐I at physiologic concentrations is an important regulator of hair follicle growth in vitro. J Invest Dermatol. 1994;102(6):857‐861. doi:10.1111/1523-1747.ep12382494
Peus D, Pittelkow MR. Growth factors in hair organ development and the hair growth cycle. Dermatol Clin. 1996;14(4):559‐572. doi:10.1016/s0733-8635(05)70384-3
Zari S. Short‐term efficacy of autologous cellular micrografts in male and female androgenetic alopecia: a retrospective cohort study. Clin Cosmet Investig Dermatol. 2021;14:1725‐1736. doi:10.2147/CCID.S334807
FDA. Public Safety Notification on Exosome Products. 2019. Accessed August 18, 2023. https://www.fda.gov/vaccines‐blood‐biologics/safety‐availability‐biologics/public‐safety‐notification‐exosome‐products